Avenue Therapeutics
A specialty pharmaceutical company that seeks to develop and commercialize therapies for the treatment of rare and neurological diseases.
As of Q1 2023, Avenue is developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABA-A α2/3 receptor positive allosteric modulator for CNS diseases, and IV Tramadol, which is in Phase III clinical development for the management of moderate-to-moderately-severe pain in adults in a medically-supervised healthcare setting.
Avenue is headquartered in Miami, Florida and was founded by Fortress Biotech.
Latest Avenue Therapeutics News & Features
24 April 2023
2 March 2023
3 October 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze